News

STATEMENT ON THE OMICRON BA.2 VARIANT

We at ACON Laboratories, Inc. have been continuously monitoring the emergence of COVID-19 variants. The Omicron variant (B.1.1.529) is currently the dominant variant circulating globally, accounting fornearly all sequences reported to GISAID. Omicron is made up of...

read more

UPDATED STATEMENT ON THE OMICRON VARIANT

ACON Laboratories, Inc. has been continuously monitoring the emergence of SARS-CoV-2 variants, including the Omicron variant. We are pleased to report that an independent evaluation conducted by the National Institutes of Health’s (NIH) RADx program has indicated that...

read more

STATEMENT ON THE OMICRON VARIANT

We at ACON Laboratories, Inc. have been continuously monitoring the emergence of SARS-CoV-2 variants and the Omicron variant is no exception. The Omicron variant is notable for the significant number of mutations in the Spike protein. Those mutations are not relevant...

read more

Flowflex™ COVID-19 Home Test Receives FDA EUA

SAN DIEGO, CA., October 4, 2021 – ACON Laboratories, Inc., a leading global medical device manufacturer for 25 years, announced today that its Flowflex™ COVID-19 Antigen Home Test has been authorized for emergency use by the U.S. Food and Drug Administration.The...

read more